Cargando…
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations
Cabazitaxel is an effective chemotherapeutic agent used in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. With the advent of new antiandrogen therapies, immune-based treatments, and radioactive-targeted therapy, there are now multiple effective and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566506/ https://www.ncbi.nlm.nih.gov/pubmed/28860817 http://dx.doi.org/10.2147/OTT.S103532 |